Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 1% melatonin for female androgenetic alopecia (randomized double-blind trial)
TCTR20201227001Phase 2Enrolling by invitation
- Sponsor
- Thammasat University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melatonin in androgenetic alopecia (AGA) (2 arms), sponsored by Thammasat University. Primary endpoints: Efficacy endpoints and Safety endpoints. Started Oct 2020; status: enrolling by invitation.
02
Drugs
melatonin
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on TCTR20201227001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201227001.